Janus Kinase Inhibition with Tofacitinib: Changing the Face of Inflammatory Bowel Disease Treatment

Author(s): Lucine Vuitton, Stéphane Koch, Laurent Peyrin-Biroulet

Journal Name: Current Drug Targets

Volume 14 , Issue 12 , 2013

Become EABM
Become Reviewer


The advent of anti-Tumor Necrosis Factor (TNF) therapy has changed the way of treating inflammatory bowel disease (IBD). However, primary and secondary failure are relatively frequent with all anti-TNF agents, which are available only as parenteral agents. Tofacitinib is an oral janus kinase (JAK) inhibitor that inhibits JAK family kinase members, in particular JAK1 and JAK3, achieving a broad limitation of inflammation by interfering with several cytokine receptors. It first proved its efficacy as an immunosuppressive regimen after renal transplantation, and was recently approved by the FDA for rheumatoid arthritis. First data in IBD are promising, especially in ulcerative colitis. Ongoing clinical trials in both UC and Crohn’s disease (CD) are needed to further explore its efficacy in CD and to better assess its safety profile.

Keywords: Crohn’s disease, immunosuppression, inflammatory bowel disease, janus kinase, tofacitinib, ulcerative colitis.

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [1385 - 1391]
Pages: 7
DOI: 10.2174/13894501113149990160
Price: $65

Article Metrics

PDF: 66